US 2024/0252502 A1 · HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF

Abstract

Provided herein are methods of treating or preventing metabolic disease with an HDAC6 inhibitor. Also provided herein are methods of treating or preventing heart failure with preserved ejection fraction with an HDAC6 inhibitor. A variety of HDAC6 inhibitors are described herein for use in treating or preventing metabolic disease or heart failure with preserved ejection fraction. In one aspect, described herein are methods of treating a human patient by orally administering an HDAC6 inhibitor, such as an inhibitor of Formula (I) or Formula (II).

Claims71

Dependent claims

A method of treating or preventing metabolic disease in a subject in need thereof, comprising administering an HDAC6 inhibitor to the subject.

Dependencies are inferred from the claim text.

Facts

Application

18/558,704Filed 4 May 2022

Priority

4 May 2021

Published

1 Aug 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 31/4245
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: oxadiazoles
A61K 31/427
Thiazoles: not condensed and containing further heterocyclic rings
A61K 31/17
Amides, e.g. hydroxamic acids: having the group >N—C—N< or >N—C—N<, e.g. urea, thiourea, carmustine
A61K 31/42
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: oxazoles

Hdac6 inhibitors for treatment of metabolic disease and hfpef

Life of this patent

Abstract

Claims71

Hdac6 inhibitors for treatment of metabolic disease and hfpef

Life of this patent

Abstract

Claims71